MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Activated microglia contribute to MPTP-induced impairment of cardiovascular function

    X. Liu, B. Wei, Q. Sun, Q. Bi, X. Shen, P. Shi (Hangzhou, China)

    Objective: To investigate the contribution of microglia in MPTP-induced loss of adrenergic neurons and impairment of cardiovascular function. Background: Parkinson’s disease (PD) is a neurodegenerative…
  • MDS Virtual Congress 2020

    An investigation of the relationships between measures of pain, physical activity levels, sleep quality and mood in people with Parkinson’s disease

    V. Nguy, B. Barry, N. Moloney, L. Hassett, C. Canning, S. Lewis, N. Allen (Sydney, Australia)

    Objective: This cross-sectional observational study explored the relationships between measures of physical activity, sleep and mood with pain in people with Parkinson’s disease (PD). Background:…
  • MDS Virtual Congress 2020

    Apomorphine improves pulmonary function in parkinsonian patients

    I. Reuter (Giessen, Germany)

    Objective: Aim of the study;  to investigate if apomorphine might  facilitate weaning from mechanical ventilation in parkinsonian patients. Background: Apomorphine is an effective treatment for PD…
  • MDS Virtual Congress 2020

    Prevalence of dysphagia and screening tools in patients with Parkinson’s disease

    H. Téllez-Lucero, O. Cárdenaz-Saenz, F. Herrera-Rodríguez, E. Escobar-Valdivia, A. Abundes-Corona, O. Esquivel-Zapata, Y. Ríos-Solís, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)

    Objective: Determine the prevalence of dysphagia in patients with Parkinson's disease (PD) and compare the Swallowing Disturbance Questionnaire (SDQ) and Eating Assessment Tool (EAT-10). Background:…
  • MDS Virtual Congress 2020

    Phenotype of Parkinson’s Disease in African Americans Using NIH Toolbox Motor Measures

    M. Bailey, G. Stebbins, S. Anderson, D. Hall (Chicago, IL, USA)

    Objective: To determine phenotypic differences using qualitative and quantitative measures between African American (AA) and white (W) patients with Parkinson’s disease (PD) at Rush University…
  • MDS Virtual Congress 2020

    Relationship between tumor and very slow Parkinson`s disease progression

    H. Mori (Kurashiki, Okayama, Japan)

    Objective: We evaluate the Parkinson`s disease patients with very slow progression. One of their clinical features are the medical history of tumor. Background: Some cancer…
  • MDS Virtual Congress 2020

    Dietary and Plasma Polyunsaturated Fatty Acids in Parkinson’s Disease

    D. Yoo, Y. Lim, T. Ahn (Seoul, Republic of Korea)

    Objective: We assessed the dietary intakes and plasma levels of polyunsaturated fatty acid (PUFA) in Parkinson's disease (PD), and their relation to motor and non-motor…
  • MDS Virtual Congress 2020

    Homer1 polymorphism in patients with Parkinson’s disease and psychosis

    A. Lenka, S. Vadivel, R. Christopher, S. Arumugham, S. Hegde, R. Yadav, P. Pal (Washington, DC, USA)

    Objective: To explore the association of psychosis in Parkinson’s disease with polymorphisms of HOMER1, a gene whose product (Homer1) is responsible for modulating the metabotropic…
  • MDS Virtual Congress 2020

    Determination of non-motor symptoms in Parkinson’s disease in Kazakhstan (on the example of the city of Almaty)

    A. Aralbayeva, A. Kondybaeva, S. Kamenova, K. Kuzhibaeva (Almaty, Kazakhstan)

    Objective: To identify non-motor symptoms in patients with Parkinson's disease, depending on the severity of the disease. Background: Parkinson's disease is a chronic disease, as…
  • MDS Virtual Congress 2020

    CVT-301 treatment provides consistent and clinically significant improvements in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) over 12 weeks

    A. Ellenbogen, A. Corbin, P. Zhao, D. Kegler-Ebo, H. Roberts (Bingham Farms, MI, USA)

    Objective: A post hoc analysis of UPDRS-III sequential changes over the 12-week treatment period of a phase 3 study. Background: CVT-301 is an inhaled levodopa…
  • « Previous Page
  • 1
  • …
  • 78
  • 79
  • 80
  • 81
  • 82
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley